Clinical trials: GLP-1
Diabetes Mellitus, Type 2
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
GLP-1 receptor agonists (GLP-1 RA) is group of antidiabetic agents very effective in lowering the plasma glucose concentration in T2DM patients .
- Trial name
- NCT04135287
- Testing
- GLP-1 receptor agonist
- Where
- Kuwait
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Dasman Diabetes Institute
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Laxity; Skin
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects
Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.
- Trial name
- NCT07217743
- Testing
- Sculptra Aesthetic
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Type 2 Diabetes Mellitus, Bone Remodeling
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
The purpose of this study is to determine changes in bone turnover markers and calcitonin following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2 diabetes.
- Trial name
- CMBD (NCT01381926)
- Testing
- exenatide, Saline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Kidney Diseases
The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels.
- Trial name
- NCT06872060
- Testing
- Glucagon, Glucagon+Exendin9-39, Sodium chloride
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Glucose Metabolism Disorders
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion
- Trial name
- NCT03181191
- Testing
- Oral glucose tolerance test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity
Carbohydrate Intake and Gut Hormone Release During Exercise
It is well known that following a single session of moderate-to-high intensity exercise individuals experience a temporary suppression of hunger and a delay in the commencement of eating.
- Trial name
- NCT04019418
- Testing
- Maltodextrin (carbohydrate), Exercise, Rest
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Kidney Functional
GLP-1: Acute Effects on Kidney Function in Healthy Men
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
- Trial name
- NCT01333163
- Testing
- Human GLP-1 (7-36) amide, Isotone NaCl
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeppe Skov
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
Patients with diabetes have high blood sugar levels (hyperglycemia) because pancreatic beta-cells no longer produce sufficient insulin.
- Trial name
- NCT00813228
- Testing
- Sitagliptin (Januvia)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Genetic Predisposition, Type2diabetes
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1.
- Trial name
- NCT06972407
- Testing
- Exendin 9-39, Saline
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Muscle Mass and Strength, Obesity & Overweight
Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment
This study aims to investigate the effect that a structured, progressive resistance exercise program may have on maintaining the muscle mass and physical function of overweight/ obese females whilst they experience a tirzepatide…
- Conditions
- Muscle Mass and Strength, Obesity & Overweight, Physical Function
- Trial name
- FLEX (NCT07457437)
- Testing
- Progressive Resistance Exercise Training Program, Habitual physical activity guidelines
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Bariatric Surgery
Incretin Hormone Antagonism After Bariatric Surgery
Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify the importance of endogenous GLP-1 and GIP…
- Trial name
- INCA-BAR (NCT03950245)
- Testing
- GLP-1 antagonism, GIP antagonism, GLP-1 and GIP antagonism
- Where
- 2 sites in Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Hypoglycemia
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
- Trial name
- NCT00745186
- Testing
- Glucagen, Mayne Glucagon
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
GLP-1, Alcohol
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
- Trial name
- TAP (NCT07758231)
- Testing
- Acute Ethanol Dose
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.
- Trial name
- NCT06996886
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion
The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.
- Trial name
- NCT00978900
- Testing
- Artificial sweeteners; Carbohydrate Sugars, Water
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Adult Participants
Effects of an Arabinoxylan-enriched Rusk on Postprandial Glucose, Insulin, Glucagon-like Peptide-1 and Appetite Responses
The aim of the present pilot randomized controlled trial is to compare the effects of the following: 1)-rusk enriched with arabinoxylans (r-rich), 2)-rusk not enriched (r-standard) on blood glucose, insulin values, glucagon like…
- Trial name
- NCT07682857
- Testing
- Enriched rusk, Standard rusk
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Turin, Italy
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Type 2 Diabetes, Stroke
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men
Type 2 diabetes mellitus, T2D is a disease characterized by an immense growing prevalence world wide with an increased risk of myocardial infarction and stroke.
- Conditions
- Type 2 Diabetes, Stroke, Myocardial Infarction
- Trial name
- NCT00256256
- Testing
- glucagon-like-peptide-1
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus